EUVIMEDEUVIMED entdecken
Crossref

Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax

Mamaev NN, Baykov VV, Shakirova AI, Kanunnikov MM, Babenko EV, Martynkevich IS, Uspenskaya OS, Vlasova JJ, Bondarenko SN

Insights in Blood Disorders · 2022

DOI: 10.33425/2771-9073.1007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Insights in Blood Disorders, 2022. Verfasst von Mamaev NN und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical and laboratory data are presented of a 29 year female patient with BAALC- and BCL-2-positive T-cell acute lymphoblastic leukemia developed from early leukemic progenitors which was treated unsuccessfully with high-dose chemotherapy and allogeneic stem cell transplant (allo-HSCT), but revealed an impressive effect of venetoclax. For reasons beyond our control, allo-HSCT with myeloablative fludarabine-busulfan (14 mg/ kg) conditioning regimen was performed at the peak of relapse when blast count in bone marrow aspirate was 77.5%, whereas level of BAALC-expressing earlier progenitors (EP) reached 186%. HSCT was ineffective, since the number of blasts on day+30 reached 86%, whereas the burden of BAALC-expressing EP decreased to the cutoff values. Later, at post-transplant stage, an impressive response to venetoclax coupled with hypomethylating agent was observed. Following allo-HSCT and combined venetoclax therapy a severe pancytopenia developed, which required the second transplantation of peripheral blood stem cells from her haplo-matched father. After transplantation hematopoietic recovery started on day 10+. Although bone marrow aspirate at this point was hypo cellular, it contained all types of granulocytic and erythroid elements and 2.2% of blasts only.

Zitieren

APA

NN, M., VV, B., AI, S., MM, K., EV, B., IS, M., OS, U., JJ, V., & SN, B. (2022). Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax. Insights in Blood Disorders. https://doi.org/10.33425/2771-9073.1007

Vancouver

NN M, VV B, AI S, MM K, EV B, IS M, et al. Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax. Insights in Blood Disorders. 2022. doi:10.33425/2771-9073.1007

BibTeX
@article{NN2022,
  author = {NN, Mamaev and VV, Baykov and AI, Shakirova and MM, Kanunnikov and EV, Babenko and IS, Martynkevich and OS, Uspenskaya and JJ, Vlasova and SN, Bondarenko},
  title = {Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax},
  journal = {Insights in Blood Disorders},
  year = {2022},
  doi = {10.33425/2771-9073.1007}
}
Kostenlos starten →